Entrada Therapeutics (TRDA) Current Deferred Revenue (2023 - 2026)

Entrada Therapeutics' Current Deferred Revenue history runs 4 years deep, the most recent figure standing at $254000.0 for Q1 2026.

• On a quarterly basis, Current Deferred Revenue fell 81.21% year-over-year to $254000.0 in Q1 2026; TTM through Mar 2026 was $254000.0, a 81.21% decrease from a year earlier, with the FY2025 full-year figure at $342000.0, down 94.75% from the prior year.
• Current Deferred Revenue retreated to $254000.0 in Q1 2026 per TRDA's latest filing, from $342000.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $148.4 million in Q3 2023 and bottomed at $254000.0 in Q1 2026.
• The 4-year median for Current Deferred Revenue is $8.0 million (2024), against an average of $39.1 million.
• Across the five-year window, Current Deferred Revenue sank 95.59% in 2025 and sank 81.21% in 2026, its largest moves.
• Year by year, Current Deferred Revenue stood at $132.3 million in 2023, then plunged by 95.08% to $6.5 million in 2024, then plunged by 94.75% to $342000.0 in 2025, then declined by 25.73% to $254000.0 in 2026.
• Per Business Quant, the three latest TRDA Current Deferred Revenue figures stand at $254000.0 (Q1 2026), $342000.0 (Q4 2025), and $351000.0 (Q3 2025).